Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 3/20 | 0.64 |
| ▸ | KIF11 | P52732 | 6/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276059 | 1.00 | PTPN5 (0.64) | PTPN5KIF11CES2CES1FFAR1 | |
| SCHEMBL2276065 | 1.00 | PTPN5 (0.64) | PTPN5KIF11CES2CES1FFAR1 | |
| SCHEMBL5451341 | 0.94 | PTPN5 (0.55) | PTPN5KIF11CES2CES1AKR1C3 | |
| SCHEMBL342466 | 0.94 | PTPN5 (0.55) | PTPN5KIF11CES2CES1AKR1C3 | |
| SCHEMBL991083 | 0.94 | PTPN5 (0.55) | PTPN5KIF11CES2CES1AKR1C3 | |
| SCHEMBL2275451 | 0.84 | PDE2A (0.51) | PTPN5KIF11CES2CES1FFAR1 | |
| SCHEMBL2275457 | 0.84 | PDE2A (0.51) | PTPN5KIF11CES2CES1FFAR1 | |
| SCHEMBL2275455 | 0.84 | PDE2A (0.51) | PTPN5KIF11CES2CES1FFAR1 | |
| SCHEMBL2276839 | 0.83 | KIF11 (0.58) | PTPN5KIF11CES2CES1FFAR1 | |
| SCHEMBL14087362 | 0.83 | PTPN5 (0.59) | PTPN5KIF11FFAR1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | PTPN5 366/4885KIF11 3904/4885CES2 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.